Literature DB >> 21161669

Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis.

Yang Mei1, Faming Pan, Jing Gao, Rui Ge, Zhenhua Duan, Zhen Zeng, Fangfang Liao, Guo Xia, Sheng Wang, Shengqian Xu, Jianhua Xu, Li Zhang, Dongqing Ye.   

Abstract

Interleukin 17 (IL-17) is a Th17 cytokine associated with inflammation, autoimmunity, and defense against some bacteria; it has been implicated in many chronic autoimmune diseases including psoriasis, multiple sclerosis, and systemic sclerosis. However, whether IL-17 plays a role in the pathogenesis of ankylosing spondylitis (AS) remains unclear. To analyze the content of IL-17 and IL-23 in the serum from patients with AS compared with health control subject, 50 patients with AS and 43 healthy volunteers were recruited. Serum IL-17 levels were examined by enzyme linked immunosorbent assay (ELISA). Statistic analyses were performed by SPSS 13.0. Results show that the serum IL-17 and IL-23 levels were significantly elevated in AS patients as compared with normal controls. Nevertheless, no associations of serum IL-17 and IL-23 levels with clinical and laboratory parameters were found; no significant difference regarding serum IL-17 and IL-23 levels was found between less active AS and more active AS. However, there was a strong positive association between the serum levels of IL-17 and IL-23 in the AS patients. Our results indicate increased serum IL-17 and IL-23 levels in AS patients, suggesting that this two cytokine may play critical roles in the pathogenesis of AS. Therefore, further studies are required to confirm this preliminary data.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21161669     DOI: 10.1007/s10067-010-1647-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  24 in total

1.  Clinical features of adult-onset ankylosing spondylitis in Korean patients: patients with peripheral joint disease (PJD) have less severe spinal disease course than those without PJD.

Authors:  H J Baek; K C Shin; Y J Lee; S W Kang; E B Lee; C D Yoo; Y W Song
Journal:  Rheumatology (Oxford)       Date:  2004-08-17       Impact factor: 7.580

2.  Protective role of IFN-gamma in collagen-induced arthritis conferred by inhibition of mycobacteria-induced granulocyte chemotactic protein-2 production.

Authors:  Hilde Kelchtermans; Sofie Struyf; Bert De Klerck; Tania Mitera; Marijke Alen; Lies Geboes; Maarten Van Balen; Chris Dillen; Willy Put; Conny Gysemans; Alfons Billiau; Jo Van Damme; Patrick Matthys
Journal:  J Leukoc Biol       Date:  2007-01-02       Impact factor: 4.962

Review 3.  T(H)-17 cells in the circle of immunity and autoimmunity.

Authors:  Estelle Bettelli; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2007-04       Impact factor: 25.606

4.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

5.  High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism.

Authors:  M Ziolkowska; A Koc; G Luszczykiewicz; K Ksiezopolska-Pietrzak; E Klimczak; H Chwalinska-Sadowska; W Maslinski
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

6.  Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis.

Authors:  Christoph Becker; Heike Dornhoff; Clemens Neufert; Massimo C Fantini; Stefan Wirtz; Sabine Huebner; Alexei Nikolaev; Hans-Anton Lehr; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Peter R Galle; Margaret Karow; Markus F Neurath
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

7.  Loss of IFN-gamma enables the expansion of autoreactive CD4+ T cells to induce experimental autoimmune encephalomyelitis by a nonencephalitogenic myelin variant antigen.

Authors:  Joseph J Sabatino; John Shires; John D Altman; Mandy L Ford; Brian D Evavold
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

8.  Increased serum interleukin 17 in patients with systemic lupus erythematosus.

Authors:  Xue-Fei Zhao; Hai-Feng Pan; Hui Yuan; Wen-Hui Zhang; Xiang-Pei Li; Gui-Hong Wang; Guo-Cui Wu; Hong Su; Fa-Ming Pan; Wen-Xian Li; Lian-Hong Li; Guo-Ping Chen; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2009-04-04       Impact factor: 2.316

9.  Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis.

Authors:  Xinwei Wang; Zhiming Lin; Qiujing Wei; Yingjuan Jiang; Jieruo Gu
Journal:  Rheumatol Int       Date:  2009-02-27       Impact factor: 2.631

10.  Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.

Authors:  Craig A Murphy; Claire L Langrish; Yi Chen; Wendy Blumenschein; Terrill McClanahan; Robert A Kastelein; Jonathon D Sedgwick; Daniel J Cua
Journal:  J Exp Med       Date:  2003-12-08       Impact factor: 14.307

View more
  85 in total

1.  IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist.

Authors:  Frank L van de Veerdonk; Angela K Stoeckman; Gouping Wu; Aaron N Boeckermann; Tania Azam; Mihai G Netea; Leo A B Joosten; Jos W M van der Meer; Ruyi Hao; Vassili Kalabokis; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

2.  Comment on "Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA".

Authors:  Liang-Ping Ye; Xue-Mei Zhan; Hua-Qing Hu
Journal:  Clin Rheumatol       Date:  2011-10-18       Impact factor: 2.980

Review 3.  Mediators of inflammation and bone remodeling in rheumatic disease.

Authors:  Anita T Shaw; Ellen M Gravallese
Journal:  Semin Cell Dev Biol       Date:  2015-10-19       Impact factor: 7.727

4.  Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results.

Authors:  Tamer A Gheita; Iman I El Gazzar; Hussein S El-Fishawy; Mohamed A Aboul-Ezz; Sanaa A Kenawy
Journal:  Clin Rheumatol       Date:  2014-01-03       Impact factor: 2.980

5.  Elevated serum levels of interleukin-17A in uveitis patients.

Authors:  Shayma Jawad; Baoying Liu; Elvira Agron; Robert B Nussenblatt; H Nida Sen
Journal:  Ocul Immunol Inflamm       Date:  2013-08-19       Impact factor: 3.070

Review 6.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

Review 7.  Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.

Authors:  John D Reveille
Journal:  Clin Rheumatol       Date:  2015-05-05       Impact factor: 2.980

Review 8.  Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis.

Authors:  Smriti K Raychaudhuri; Ankit Saxena; Siba P Raychaudhuri
Journal:  Clin Rheumatol       Date:  2015-05-05       Impact factor: 2.980

Review 9.  Pathogenesis of ankylosing spondylitis - recent advances and future directions.

Authors:  Vidya Ranganathan; Eric Gracey; Matthew A Brown; Robert D Inman; Nigil Haroon
Journal:  Nat Rev Rheumatol       Date:  2017-04-27       Impact factor: 20.543

10.  [Update: enterogenic spondylarthritis].

Authors:  Elisabeth Märker-Hermann
Journal:  Z Rheumatol       Date:  2021-05-27       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.